-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncolys BioPharma nine-month net loss narrows 31% to JPY 1.12 billion; nine-month net sales rise to JPY 527.81 million

PUBT·11/06/2026 06:44:02
Listen to the news
Oncolys BioPharma nine-month net loss narrows 31% to JPY 1.12 billion; nine-month net sales rise to JPY 527.81 million
  • Oncolys BioPharma narrowed its net loss 31% year-over-year to JPY 1.12 billion for the nine months ended September 30, 2026.
  • Net sales rose year-over-year to JPY 527.81 million.
  • Telomelysin Injection secured full marketing approval in Japan and launched in August 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolys BioPharma Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.